DKSH Holding AG/€DKSH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About DKSH Holding AG
DKSH Holding AG operates as a market expansion services provider, primarily serving clients in the consumer goods, healthcare, performance materials, and technology sectors. The company offers services across sourcing, marketing, sales, distribution, and after-sales, helping businesses expand into new markets. Established in 1865, DKSH is headquartered in Zurich, Switzerland, and has a significant presence across the Asia-Pacific region. DKSH's strategic position is bolstered by its extensive local knowledge and network, enabling efficient operations and market penetration. The company's comprehensive service model supports its clients in achieving growth in diverse and complex markets.
- Ticker
- €DKSH
- Sector
- Industrials
- Primary listing
- XGAT
- Employees
- 24,942
- Headquarters
- Zurich, Switzerland
- Website
- www.dksh.com
DKSH Holding AG Metrics
BasicAdvanced
€5.4B
22.86
€3.66
0.43
€2.71
3.24%
Price and volume
Market cap
€5.4B
Beta
0.43
52-week high
€72.80
52-week low
€58.20
Average daily volume
89K
Dividend rate
€2.71
Financial strength
Current ratio
1.38
Quick ratio
0.918
Long term debt to equity
0.372
Total debt to equity
0.43
Dividend payout ratio (TTM)
76.58%
Interest coverage (TTM)
20.12%
Profitability
EBITDA (TTM)
400.639
Gross margin (TTM)
7.87%
Net profit margin (TTM)
1.92%
Operating margin (TTM)
2.90%
Effective tax rate (TTM)
27.98%
Revenue per employee (TTM)
€477,980
Management effectiveness
Return on assets (TTM)
3.66%
Return on equity (TTM)
12.63%
Valuation
Price to earnings (TTM)
22.865
Price to revenue (TTM)
0.438
Price to book
2.93
Price to tangible book (TTM)
5.59
Price to free cash flow (TTM)
15.79
Free cash flow yield (TTM)
6.33%
Free cash flow per share (TTM)
5.304
Dividend yield (TTM)
3.24%
Forward dividend yield
3.24%
Growth
Revenue change (TTM)
-1.34%
Earnings per share change (TTM)
12.39%
3-year revenue growth (CAGR)
-0.94%
10-year revenue growth (CAGR)
0.83%
3-year earnings per share growth (CAGR)
2.84%
10-year earnings per share growth (CAGR)
1.91%
3-year dividend per share growth (CAGR)
5.16%
10-year dividend per share growth (CAGR)
6.76%
Bulls say / Bears say
First-half sales grew 4.9% at constant exchange rates, including 4.1% organic growth, the strongest first-half revenue growth in three years. DKSH reaffirmed its outlook for higher Core EBIT in 2026 than in 2025. (DKSH)
Free cash flow rose to CHF 147.7 million, with cash conversion of 130.8%, while corrected earnings per share increased 10.6% to CHF 1.56. This cash generation gives DKSH scope to fund investment and acquisitions without relying heavily on debt. (DKSH)
DKSH is broadening its healthcare reach through acquisitions, including NewBridge Pharmaceuticals, which would establish a platform across 14 Middle East and North Africa markets. This may diversify its growth base and extend its commercial outsourcing capabilities beyond its established markets. (EQS News)
Revenue growth is not yet translating cleanly into reported operating profit: the first-half Core EBIT margin slipped to 3.0% from 3.1%, and Core EBIT fell 3.5% in Swiss francs. Currency translation reduced sales by 5.8% and weighed more heavily on profit. (DKSH)
Profitability remains vulnerable in major businesses: Consumer Goods’ margin fell to 2% amid promotions and value-seeking customers, while upfront healthcare contract costs may weigh on margins into 2027. Traditional healthcare distribution also carries thin margins, limiting how much sales growth can lift profits. (Investing.com)
The valuation leaves less room for execution setbacks: after the share-price rise, Berenberg cut its rating to Hold and saw only about 8% upside to its revised target. It also argued that meeting DKSH’s full-year guidance requires a strong second half, while its earnings forecasts sit below consensus. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Upcoming events
No upcoming events
Funds containing DKSH Holding AG
AllUSDEURGBP
Fund name | Fund size | €DKSH weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.20% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.20% |
L&G Global Quality Dividends£LDGG | $353M | 0.06% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.03% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.